Latest Financial Results

2018

Year End Results

Ended Oct 31, 2018

Stock Information

Symbol

ANIX

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

By using the body's immune system, Anixa Biosciences is taking multiple approaches to fighting cancer-developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. Anixa is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Anixa is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.

Logo Itus

Latest News & Events

Anixa Biosciences to Present at Moffitt Cancer Center's Business of Biotech Conference

Read More...

Anixa Biosciences Conference Call Recording Available on Company Website

Read More...

Anixa Biosciences CAR-T Cancer Therapy Patent Receives Notice of Allowance

Read More...

Cancer Fact: Approximately 40 million mammograms are conducted annually.